Melanotan II
Cyclic α-MSH analogue, the parent of bremelanotide. Unapproved; significant adverse-event profile.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Also: MT-II
Cyclic α-MSH analogue, the parent of bremelanotide. Unapproved; significant adverse-event profile.
Evidence Intelligence Score™
- Preclinical← current
- Pilot human
- RCT
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data3.8
- Safety maturityFollow-up depth and adverse-event signal2.1
- Mechanism confidencePathway specificity and clarity6.2
- Clinical readinessDistance to physician-prescribable use2.8
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts3.0
- Long-term dataFollow-up beyond initial trial windows1.8
- Translational confidenceAnimal → human signal preservation4.4
Mechanistic and preclinical evidence is suggestive; controlled human trials are not yet on the index.
Translational confidence is limited until pre-registered human trials reproduce the preclinical signal.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: speculative. A grade upgrade requires controlled human evidence, not additional preclinical confirmation.
Libido & arousal
1 study- moderateWessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N
Melanotan-II 0.025 mg/kg SC significantly increased self-reported sexual desire scores in healthy men vs placebo.
RCTn=202000unreviewed
Tanning & pigmentation
1 study- moderateDorr RT, Lines R, Levine N, et al.
Daily SC melanotan-II produced dose-dependent skin darkening (reflectance measurements) in human volunteers; nausea and flushing common at higher doses.
Observationaln=281996unreviewed
Erectile function
1 study- moderateWessells H, Fuciarelli K, Hansen J, et al.
Melanotan-II (0.025 mg/kg SC) produced clinically significant erections in 8/10 men with psychogenic ED vs 0/10 with placebo.
RCTn=101998unreviewed
Erectile function
1 regimenNausea (most common, dose-limiting), facial flushing, decreased appetite, yawning, spontaneous erections. Not approved by any regulator.
All published clinical use was short-term; no approved maintenance regimen exists.
Libido & arousal
1 regimenNausea, flushing; non-approved investigational use.
Single-dose study; no longitudinal libido data.
Tanning & pigmentation
1 regimenNausea, facial flushing, decreased appetite; case reports link melanotan-II use to changes in nevi/melanoma — dermatologic surveillance advised.
Pigmentation faded after discontinuation. Long-term safety not established.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
1 brand across three tiers.
Research-use only
1 brandSold by chemical suppliers labelled 'for laboratory research only — not for human consumption'. No pharmaceutical-grade QC, no medical oversight. Listed for transparency.